CClinicalTrials.gg
CompletedNCT03104673MSP_ExtUpdated Sep 2, 2026

Molecular Signature Children

An observational study in Preterm Birth, sponsored by University of Oxford. Completed at 1 site in Thailand. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by University of Oxford · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
380
Sex
All
01

Study summary

Preterm birth (PTB) occurs before 37 weeks of gestation and is a major cause of neonatal mortality and morbidity. PTB results from heterogeneous influences. One of them is the inherited predisposition of spontaneous PTB, and another is the change in the placental microbial composition as this can cause infections, which lead to inflammation, a common cause of preterm birth. Interestingly, maternal periodontal disease is an independent risk factor for PTB, low birth weight and fetal growth restriction. Immune responses to infectious events or inflammation as well as genetic predisposition to inherited conditions have successfully been studied by using assessing genetic expression profiling. The molecular signature is sets of genes, proteins, genetic variants or other variables that can be used as markers for a particular phenotype.

Child morbidity from malnutrition resulting in poor growth and stunting remains a major public health issue that affects the local population just like PTB. While risk factors for malnutrition are multifaceted, there is also a hypothesized causal link between early gut microbiome disruption that leads to chronic malnutrition in otherwise healthy infants.

Molecular signatures including the intestinal microbiome development of preterm infants will be evaluated and compared to the term (≥37 weeks' gestation) counterparts. Moreover, a comprehensive examination of possible factors associated with poor growth and poor motor- and neurodevelopment will be assessed.

In this extension study: The primary goal for the child is to evaluate the perturbation in the development of the genomic profile including intestinal microbial habitat from children in a rural and limited-resource setting from birth to two years of life.

Read the detailed description

Rationale:

The importance of early life epigenetics is now recognized to have direct implications for health in later life and a consistent limitation expressed in peer reviewed publications has been the small sample size of the studies. Rather than establish a separate cohort to study epigenetics in young children in this environment this extension study of TMEC 15-062 (Molecular signature of Karen and Burmese women on the Thailand--Myanmar border) aims to build on the detailed sampling of the mothers to not only identify biomarkers of preterm labor but also to understand high rates of stunting and anaemia in this area, and possibly develop predictive tools or pave new ways for prevention in the future.

Moreover, a non-invasive intervention in the form of nutrition and WASH counselling may provide information on whether this form of engagement can positively influence child development, prevent malnutrition and whether perturbations in the infants molecular signature can be observed.

In addition, the mothers exposed to the sampling procedure at birth in this study will be able to make a well-informed decision about whether they wish to enrol the child in such a study.

The rationale for the planned samples in children born to mothers who participated in the TMEC 15-062 study are summarized in the following text:

Child gut microbiome and assessment of nutrition from stool samples (Risk-none) The intestinal ecosystem is very dynamic, especially in the first period of life, as it needs to evolve from scratch, hence investigators want to follow children and analyse stool samples in first 24 month of life. investigators propose to assess what kind of impact the gut microbiome has on the child's growth and development. Since exposure to helminths is common in the study population, children stool samples will also be used to examine for helminthic infestations.

This point would also include a home visit as part of nutrition evaluation by questionnaire and direct observation (food preparation including hygiene, child food content, feeding patterns) to relate to microbiome.

Early childhood Transcriptome from capillary blood (Risk-minimum) This point will enable us to understand whether preterm infants have different gene expression than their term counterparts and if so, how it evolves in the early period of life. Moreover, specific signals for children at risk for or suffering from malnutrition or stunting resulting from gastrointestinal inflammation or barrier disruption could be picked up. Total blood 0.85 mL in 2 years.

Early childhood detection of anaemia from capillary blood (Risk-minimum) Anaemia will be treated and iron supplement effect on gut microbiome analysed. Total blood 0.85 mL in 2 years.

Early childhood detection of soil transmitted helminth infection from stool sample (Risk-none) Helminth infection will be treated and the effect on gut microbiome analysed. Stool sample each visit.

Child growth assessment and evaluation of motor and neurocognitive development (Risk-none) Premature infants have a higher risk for lifelong health and development problems. Investigators propose to follow the children's over the period of 2 years to assess their growth and their neurocognitive and motor development. Preterm children's growth and development will be compared to term neonates. The recommended schedule of growth assessment in healthy children is (1, 2, 4, 6, 9, 12, 18, 24 months). In this study children will be followed more frequently: monthly in the first year of life and 3 monthly in the 2nd year of life (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 18, 21, 24 months). The reasons for this include: the objective of the root study TMEC 15-062 which is on preterm infants who require closer follow up, to relate perturbations of biomarkers to stunting, and in this mobile population scheduled visits may be missed so a more flexible arrangement for checking anthropometry at any monthly visit in the first year of life reduces the chance that poor growth is not identified.

In addition, the growth and development of children born to mothers who had a febrile episode during pregnancy will be compared to children whose mothers did not experience fever episodes during pregnancy.

Children with poor growth or malnutrition will be given supplementary nutrition and nutrition advice will be given to the mother.

This study was funded by Sidra Medical and Research. Grant reference number: B9R01250

02

Conditions studied

  • Preterm Birth

Browse trials for

Keywords

  • Molecular signature
  • Thailand-Myanmar border
03

In context

Premature Birth

2,554 studies on the registry are indexed under Premature Birth; 498 are open to participants now.

This study's enrollment of 380 is above the median of 112 across 777 observational studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

University of Oxford is the lead sponsor of 794 studies on the registry; 117 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Approximately 400 children born from pregnant women who are attending antenatal care (ANC) clinics at Shoklo Malaria Research Unit and enrol into study TMEC 15-062. A subgroup of infants born to mothers with an uneventful pregnancy, normal vaginal clinic birth at term (estimated age of ≥ 37 weeks) will be approached and invited to participate in the randomised component of the trial.

Inclusion criteria

  • Karen or Burmese pregnant woman in study TMEC 15-062 who are willing to have their offspring (children) comply with all study requirements
  • Pregnant woman is willing and able to give informed consent for her child to participate in this study

Exclusion criteria

Exclusion Criteria:

  • Children (in the investigators opinion) with any social or physical condition which would make it difficult to comply with study requirements

Inclusion Criteria for water, sanitation and hygiene (WASH) radomization

  • Mother enrolled to MSP (TMEC 15-062) and child enrolled in MSP_Ext (TMEC 17-008)
  • Term pregnancy (gestational age ≥37 weeks)
  • Clinic birth
  • Normal new-born
  • Post-partum mother willing to have home visits
  • Post-partum mother willing and able to give informed consent to participate in this study

Exclusion Criteria for water, sanitation and hygiene (WASH) randomization

  • Lives too far to make home visits feasible
  • Home situation unstable and likely to move before the child is 9 months old
  • Social situation that would make it difficult for the mother to comply
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
380 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Characterization of the molecular signature of child

    Early childhood Transcriptome from capillary blood

    Time frame: at birth

  2. Characterization of the molecular signature of child

    Early childhood Transcriptome from capillary blood

    Time frame: 1 year

  3. Characterization of the molecular signature of child

    Early childhood Transcriptome from capillary blood

    Time frame: 2 years

  4. Proportions of nutrition and water, sanitation and hygiene (WASH) behaviours in home-based compared to clinic-based care

    Time frame: 9 months

Secondary outcomes

  1. Proportion of children with biomarkers perturbations associated with poor child growth

    Describe the biomarkers predictive

    Time frame: From birth to two years of life.

  2. Proportion of children with biomarkers perturbations associated with neurocognitive and motor development

    Describe the biomarkers predictive

    Time frame: From birth to two years of life.

  3. Proportion of children with biomarkers perturbations associated with anaemia

    Describe the biomarkers predictive

    Time frame: From birth to two years of life.

  4. Association between nutrition and water, sanitation and hygiene (WASH) behaviours and biomarker signature perturbations in children

    Time frame: 9 months

07

Study locations

1 site
  • Shoklo Malaria Research Unit
    Tak, Mae Sot 63110, Thailand
08

References and documents

Publications

  • Singh P, Al Mohannadi N, Murugesan S, Almarzooqi F, Kabeer BSA, Marr AK, Kino T, Brummaier T, Terranegra A, McGready R, Nosten F, Chaussabel D, Al Khodor S. Unveiling the dynamics of the breast milk microbiome: impact of lactation stage and gestational age. J Transl Med. 2023 Nov 6;21(1):784. doi: 10.1186/s12967-023-04656-9. PubMed 37932773 ↗

Individual participant data

Plan to share: Yes — Volunteer's data and results from blood analyses stored in our database may be shared with other researchers to use in the future. However, the other researchers will not be given any information that could identify the subject.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03104673
Lead sponsor
University of Oxford
Collaborators
Sidra Medicine
Responsible party
Sponsor
First posted
Apr 7, 2017
Start date
Apr 30, 2017
Primary completion
Jan 28, 2021
Completion
Feb 12, 2021
Last update
Sep 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion